<DOC>
	<DOCNO>NCT02437890</DOCNO>
	<brief_summary>Primary objective : To assess efficacy safety different dose regimen ALX-0061 administer subcutaneously ( s.c. ) subject moderate severe active , seropositive SLE compare placebo . Secondary objective : To assess pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , immunogenicity , flare rate , steroid reduction health-related quality life , different dose regimens ALX-0061 .</brief_summary>
	<brief_title>A Phase II Study Evaluate Safety Efficacy ALX-0061 Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>1 . Man woman ≥ 18 year &lt; 65 year age 2 . Have diagnosis SLE least 6 month prior screen fulfill 1997 American College Rheumatology ( ACR ) 2012 Systemic Lupus International Collaborating Clinics ( SLICC ) classification criterion 3 . Have moderate severe active SLE 4 . Have seropositive disease screen 5 . Subject must least one treatment SLE list protocol 6 . Others define protocol 1 . Have A score revise BILAG2004 mucocutaneous and/or musculoskeletal system screen baseline organ system clinically assess 2 . Have systemic inflammatory disease SLE 3 . Clinically significant infection treat needing treatment 3 . Any active recurrent viral infection base Investigator´s clinical assessment make subject unsuitable study 4 . Have receive prior therapy block IL6 pathway 5 . Others define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>